Multiple Myeloma

Five-year results from cohort A of CARTITUDE-2, presented at the International Myeloma Society Annual Meeting, show long, treatment-free remissions in lenalidomide-refractory patients who had 1 to 3 prior lines of therapy.

UAB experts said new bladder cancer, myeloma, and lung cancer therapies are changing care, but access and costs remain barriers.

Clinicians from University of Chicago Medicine, Northwestern Medicine, and Loyola Medicine said bispecific antibodies for early-relapse myeloma can be given safely outside the hospital, but staffing, after-hours triage, and community confidence have yet to catch up.

Myeloma faculty from UT Southwestern Medical Center and pharmacy leaders from Texas Oncology discussed how teclistamab- and talquetamab-based regimens are reshaping early relapse in multiple myeloma. Observation-stay economics and physician comfort, not clinical data, are slowing delivery closer to home.

These phase 3 EXCALIBER-RRMM findings build on earlier MRD-negative complete response results supporting FDA approval of the iberdomide-based regimen.

North Carolina experts discussed CLL, breast cancer, and myeloma treatments and how to expand access to complex cancer care beyond academic centers.

At a Stakeholder Interchange convened by The American Journal of Managed Care® in Tampa, Florida, an academic-community mix of hematologist-oncologists and pharmacists debated prior authorization, site-of-care payment disparities, and how aggressively to push bispecific antibody regimens to community practices treating patients with relapsed/refractory multiple myeloma.

In an AJMC stakeholder interchange, moderator Sandra Susanibar-Adaniya, MD, MS, of Penn Medicine, led academic and community clinicians through the operational, safety, and reimbursement challenges of moving teclistamab-and talquetamab-based regimens into earlier lines of relapsed/refractory multiple myeloma and into outpatient, community-based care.

At a Stakeholder Interchange convened by The American Journal of Managed Care® in Houston, Texas, oncologists and pharmacists from academic and community practices debated how teclistamab- and talquetamab-based regimens stack up against CAR T-cell therapy in second-line multiple myeloma, and what it will take—staffing, caregiver support, hospital partnerships, and payer buy-in—to move step-up dosing out of the hospital and into the clinic.

Patient factors and access barriers are reshaping treatment sequencing and individualized care for relapsed multiple myeloma, Amandeep Godara, MBBS, said.

Five August FDA approvals introduced novel therapies across vaccines, neurology, oncology, myeloma, and dermatomyositis, despite some regulatory pushback.

The final part explores individualized CAR T and bispecific therapy selection in multiple myeloma and the need for stronger academic-community collaboration.

Amandeep Godara, MBBS, explained that rural patients with multiple myeloma face various barriers to immunotherapies that may delay treatment.

Amandeep Godara, MBBS, discusses how patient factors, disease burden, and logistics guide treatment decisions in relapsed/refractory multiple myeloma.

For Xavier Leleu, MD, PhD, there is opportunity to ensure that therapeutic advances are accompanied by advances in how those therapies are delivered.

Swarup Kumar, MD, of UConn Health, says iberdomide plus dara-dex fills a niche for relapsed disease in patients who lack access to CAR T or bispecifics.

She frames the IberDd approval as more than the addition of 1 more regimen to a crowded relapsed/refractory myeloma armamentarium.

The cereblon E3 ligase modulator, or CELMoD, also received a breakthrough therapy designation from the FDA.